Experts back Keralam’s generic SMA drug push, cite 97% cost reduction
Health experts and public health activists have strongly backed Kerala's decision to introduce affordable generic alternatives for treating Spinal Muscular Atrophy (SMA). The shift highlights a dramatic 97% reduction in treatment costs, making essential care vastly more accessible for patients. Previously, families relied heavily on expensive branded versions like Roche's risdiplam, which cost upwards of lakhs. In contrast, local generic options by manufacturers like Natco bring down monthly medical expenses substantially. While pharmaceutical giants have raised legal objections in the Delhi High Court to block commercial distribution, medical professionals emphasize that rigorous bioequivalence standards and regulatory approvals ensure patient safety. Public health advocates argue that supporting indigenous manufacturing challenges high-cost global patent monopolies and ultimately helps save vulnerable lives by lowering financial burdens on families dealing with rare genetic disorders.
The Key points
- Medical experts and activists strongly support Kerala's rollout of generic SMA treatments.
- The initiative delivers a remarkable 97% reduction in overall patient treatment costs.
- Natco’s generic risdiplam version significantly cuts monthly expenses compared to branded alternatives.
- Branded formulations distributed earlier by multinational companies were prohibitively expensive for common families.
- Roche filed a legal petition in the Delhi High Court against the generic distribution.
- Local generic medications must undergo strict bioequivalence testing under Indian drug regulations.
- Public health advocates claim challenging global pharma monopolies protects low-cost domestic healthcare options.
- Spinal Muscular Atrophy is a rare, severe genetic condition causing progressive muscle deterioration.
- State health officials cleared the low-cost medicines following thorough expert committee recommendations.
- Affordable generic alternatives offer renewed hope for long-term and sustainable rare disease management.
Disclaimer: This preview includes title, image, and description automatically sourced from the original website (www.newindianexpress.com) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
